Valuation: Glaukos Corporation

Capitalization 6.7B 5.76B 5.23B 5.01B 9.15B 617B 9.48B 61.39B 24.58B 294B 25.14B 24.6B 1,052B P/E ratio 2026 *
-142x
P/E ratio 2027 * 425x
Enterprise value 6.52B 5.6B 5.09B 4.88B 8.91B 601B 9.23B 59.75B 23.92B 287B 24.46B 23.94B 1,023B EV / Sales 2026 *
10.6x
EV / Sales 2027 * 8.21x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day-2.05%
1 week-5.96%
Current month-5.16%
1 month+0.59%
3 months+5.23%
6 months+21.56%
Current year+1.13%
1 week 112.66
Extreme 112.66
121.27
1 month 103.55
Extreme 103.55
123.16
Current year 93.96
Extreme 93.96
130.23
1 year 73.16
Extreme 73.16
130.23
3 years 44.26
Extreme 44.26
163.71
5 years 33.33
Extreme 33.33
163.71
10 years 15
Extreme 15
163.71
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2001
Director of Finance/CFO 56 01/04/2022
President 50 01/04/2022
Director TitleAgeSince
Chairman 65 31/12/2021
Director/Board Member 71 01/07/2014
Director/Board Member 58 01/07/2014
Change 5d. change 1-year change 3-years change Capi.($)
-2.03%-5.96%+1.85%+134.48% 6.7B
-1.53%-2.65%-5.02%+40.55% 146B
-2.34%-3.33%+11.89%+8.23% 15.17B
-0.19%-4.67%-18.17%-66.60% 6.08B
-0.15%-5.95%+33.60%+28.67% 2.67B
+0.71%-1.62%-16.81%-24.24% 2B
+0.97%+6.84%+17.10%-15.58% 1.88B
-1.42%-6.88%-64.04%-76.18% 1.84B
-2.33%+0.90%-31.80%-55.06% 1.48B
Average -0.92%+1.38%-7.93%-2.86% 20.44B
Weighted average by Cap. -1.46%-0.62%-3.95%+34.38%

Financials

2026 *2027 *
Net sales 613M 527M 479M 459M 838M 56.53B 868M 5.62B 2.25B 26.96B 2.3B 2.25B 96.28B 782M 673M 611M 586M 1.07B 72.13B 1.11B 7.17B 2.87B 34.4B 2.94B 2.87B 123B
Net income -50.33M -43.28M -39.27M -37.67M -68.78M -4.64B -71.26M -461M -185M -2.21B -189M -185M -7.9B 14.65M 12.6M 11.43M 10.96M 20.02M 1.35B 20.74M 134M 53.77M 644M 54.99M 53.81M 2.3B
Net Debt -180M -155M -140M -135M -246M -16.57B -255M -1.65B -660M -7.9B -675M -660M -28.23B -276M -237M -215M -206M -377M -25.43B -391M -2.53B -1.01B -12.13B -1.04B -1.01B -43.31B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Employees
1,094
Date Price Change Volume
05/03/26 114.19 $ -1.02% 9,318
04/03/26 115.37 $ -2.02% 301,904
03/03/26 117.75 $ -2.78% 589,484
02/03/26 121.12 $ +0.60% 1,171,415
27/02/26 120.40 $ -0.85% 614,602
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
115.37USD
Average target price
134.79USD
Spread / Average Target
+16.83%

Quarterly revenue - Rate of surprise